Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Dr Joyce F Liu, Dr Mansoor Raza Mirza and Dr David M O’Malley, moderated by Dr Kathleen N Moore, including the following topics:
Introduction (0:00) Current Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:06) Potential Role of Immunotherapeutic Strategies for Advanced OC — Dr O’Malley (25:12) Incorporation of Novel Therapies into the Management of Relapsed/Refractory OC — Dr Moore (48:23) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Mirza (1:06:59) CME information and select publications

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics:
Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00) Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56) Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52) Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11) Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56) Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39) CME information and select publications

Featuring an interview with Dr Kanwal Raghav, including the following topics:
Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:00) Case: A woman in her mid 50s with multiregimen-refractory metastatic CRC receives T-DXd on a clinical trial (11:19) Case: A woman in her early 60s with advanced intrahepatic cholangiocarcinoma receives zanidatamab on a clinical trial (18:11) Molecular pathways and mechanisms of HER2 in cancer; clinical implications and future directions for gastrointestinal cancers (20:33) Evolving paradigm surrounding HER2 and other oncogene-addicted targets (29:32) CME information and select publications

Featuring perspectives from Dr Bita Fakhri, including the following topics:
Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00) 6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36) Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28) 57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28) Current clinical role of MRD testing for CLL (28:11) Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43) 6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57) Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30) Recent updates for the management of double-refractory CLL (58:05) Novel therapies under investigation for patients with CLL/SLL (1:10:57) Key findings guiding the clinical management of Richter’s transformation (1:13:44) Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 2: Other Considerations in the Management of CRC — Arvind Dasari, MD, MS
CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 1: Targeted Treatment Approaches for Colorectal Cancer (CRC) — Thierry André, MD
CME information and select publications